Trial · NCT00853047
Results by group63
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 63
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Drug-related TEAE in the Core Phase | Placebo Core Phase | Any TEAE | 4 | Participants | |
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Drug-related TEAE in the Core Phase | Telotristat Etiprate 150 mg Core Phase | Any TEAE | 3 | Participants | |
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Drug-related TEAE in the Core Phase | Telotristat Etiprate 250 mg Core Phase | Any TEAE | 3 | Participants | |
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Drug-related TEAE in the Core Phase | Telotristat Etiprate 350 mg Core Phase | Any TEAE | 2 | Participants | |
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Drug-related TEAE in the Core Phase | Telotristat Etiprate 500 mg Core Phase | Any TEAE | 9 | Participants | |
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Drug-related TEAE in the Core Phase | Placebo Core Phase | Related TEAEs | 3 | Participants | |
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Drug-related TEAE in the Core Phase | Telotristat Etiprate 150 mg Core Phase | Related TEAEs | 3 | Participants | |
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Drug-related TEAE in the Core Phase | Telotristat Etiprate 250 mg Core Phase | Related TEAEs | 0 | Participants | |
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Drug-related TEAE in the Core Phase | Telotristat Etiprate 350 mg Core Phase | Related TEAEs | 2 | Participants | |
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Drug-related TEAE in the Core Phase | Telotristat Etiprate 500 mg Core Phase | Related TEAEs | 6 | Participants | |
| Number of Participants With Any TEAE in the Open-Label Extension Phase | Telotristat Etiprate Open-Label Extension Phase | 18 | Participants | ||
| Change From Baseline in Mean Number of Bowel Movements (BMs) Per Day | Placebo Core Phase | 0.82 | Standard Deviation 0.435 | bowel movements/day | |
| Change From Baseline in Mean Number of Bowel Movements (BMs) Per Day | Telotristat Etiprate 150 mg Core Phase | -1.37 | Standard Deviation 1.514 | bowel movements/day | |
| Change From Baseline in Mean Number of Bowel Movements (BMs) Per Day | Telotristat Etiprate 250 mg Core Phase | -2.17 | Standard Deviation 2.259 | bowel movements/day | |
| Change From Baseline in Mean Number of Bowel Movements (BMs) Per Day | Telotristat Etiprate 350 mg Core Phase | -0.20 | Standard Deviation 0 | bowel movements/day | |
| Change From Baseline in Mean Number of Bowel Movements (BMs) Per Day | Telotristat Etiprate 500 mg Core Phase | -0.71 | Standard Deviation 2.048 | bowel movements/day | |
| Change From Baseline in Weekly Mean Stool Form | Placebo Core Phase | -0.07 | Standard Deviation 0.222 | units on a scale | |
| Change From Baseline in Weekly Mean Stool Form | Telotristat Etiprate 150 mg Core Phase | -0.50 | Standard Deviation 0.755 | units on a scale | |
| Change From Baseline in Weekly Mean Stool Form | Telotristat Etiprate 250 mg Core Phase | 0.00 | Standard Deviation 0.141 | units on a scale | |
| Change From Baseline in Weekly Mean Stool Form | Telotristat Etiprate 350 mg Core Phase | 0.00 | Standard Deviation 0 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00853047/results